Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619001661167
Ethics application status
Approved
Date submitted
2/09/2019
Date registered
27/11/2019
Date last updated
27/11/2019
Date data sharing statement initially provided
27/11/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Stress augmentation of exposure therapy: Mechanisms and implications for relapse
Query!
Scientific title
Effects of acute stress on the strength and durability of Extinction Learning: Implications for Exposure-based treatment and Relapse Prevention
Query!
Secondary ID [1]
299104
0
Nil known
Query!
Universal Trial Number (UTN)
U1111-1239-1812
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Spider Phobia
314154
0
Query!
Specific Phobia
314155
0
Query!
Anxiety Disorders
314172
0
Query!
Condition category
Condition code
Mental Health
312524
312524
0
0
Query!
Anxiety
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Virtual Reality Exposure Therapy to spiders
2 individual, face-to-face weekly treatment sessions will be conducted using virtual reality (VR) goggles. The total duration of the intervention will be three weeks (including 2 exposure treatments, as well as pre- and post-assessment procedures). Follow-Up assessment will be conducted 3 months later. Exposure will involve a set of guided exposure tasks to VR spiders for approx. 1 hour each session. This will be administered individually by a trained psychologist. On the first treatment day, exposure tasks will include the observation of a virtual spider in a virtual kitchen and participants will be asked to approach the spider as closely as they can using their 3D wand to navigate through the virtual world. Participants will then be required to touch the virtual spider with their virtual hand and the spider will respond by fleeing (without tactile feedback). On the second treatment day (one week later), participants will be encouraged to pick a vase where an animated spider with wiggly legs will drift to the floor of the virtual kitchen. They will then be required to touch the virtual spider image with their cyberhand to explore the virtual spider. Simultaneously, their real hand will explore a toy spider attached in order to allow the spider to feel furry and more tangible (adapted from Hoffmans, 2002). SUDs (subjective units of distress) ratings will be reported every 30 seconds. SUDS < 30 will be the criterion used to define the completion of an exposure task. Participants will be instructed not to use cognitive avoidance strategies and this will be measured with several questions afterwards. Adherence to the treatment will be monitored via clinical observation and clinician's ratings of client's engagement, the severity of fear and avoidance.
Psychoeducative material about exposure therapy will be provided orally and using a handout designed specifically for this study. It will involve discussion of the purpose and benefits of exposure therapy, the role of avoidance and safety behaviours in maintaining anxiety/fear in the long term and the evidence for VR exposure treatment.
This condition will include a stress manipulation, the Socially Evaluated Cold Presser Task (SECPT) 20 minutes prior to exposure therapy. The SECPT is designed to elevate cortisol (stress hormone levels). It involves the immersion of one's dominant hand into a basin with ice-cold water (0-2 degrees Celsius) for 3 minutes whilst being recorded by a video camera and observed by a researcher. Participants will be instructed to submerge their hand including their wrist and they will not be informed of the duration of the SECPT.
Query!
Intervention code [1]
315369
0
Behaviour
Query!
Comparator / control treatment
The exposure-based treatment sessions for the control group will include all the same elements as the treatment (including psychoeducative material and exposure tasks in a kitchen context) in the equivalent order and the same timing. However, the stress procedure will be replaced with a control procedure. That is, participants will immerse their dominant hand into warm water (35-37 degrees Celsius) with no recording or experimenter present.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
321170
0
Change in the Behavioural Avoidance Test (BAT) with spiders using VR goggles
BAT involves short VR exposure task to a spider and calculating distance between VR spider and participant. VR context will differ between post- treatment and follow-up assessment. VR spider presented in a garden at post-treatment and in a Kitchen ( the treatment context) at follow-up.
Query!
Assessment method [1]
321170
0
Query!
Timepoint [1]
321170
0
1 time at pre-treatment (baseline), post- treatment( Week 3-primary endpoint 1) and follow-up assessment ( 12 weeks after final treatment session or 14 weeks post-enrolment-primary endpoint 2).
There are two primary endpoints in order to assess group differences in the return of fear following a change in context ( research question 1) and overtime ( research question 2)
Query!
Secondary outcome [1]
374155
0
Change in spider-fear-related symptoms
The Spider Phobia Questionnaire (Klorman et al., 1974) and Fear of Spider questionnaire (Symanski, 1995) will be employed
Query!
Assessment method [1]
374155
0
Query!
Timepoint [1]
374155
0
1 time at pre-treatment (baseline), post-treatment (Week 3) and follow-up-treatment (Week 14)
Query!
Secondary outcome [2]
374156
0
Free salivary Cortisol
This will be a marker of HPA axis activity and stress manipulation check (SECPT). Saliva will be collected using the Salivette sampling devices.
Query!
Assessment method [2]
374156
0
Query!
Timepoint [2]
374156
0
10 samples will be collected per participant.
Baseline saliva samples will be collected at pre-treatment (Week 1), post-treatment( Week 2) and follow-up assessment ( Week 14) immediately before the BAT. An additional baseline saliva sample will be taken in treatment session 2 ( Week 2), 5 min prior to the stress/control procedure.
In treatment session 1 and 2( Weeks 1 and 2), saliva samples will be collected 1, 20 and 35 min after the stress/control procedure.
Query!
Secondary outcome [3]
374189
0
Alpha Amylase activity
This will be collected using Salivette sampling devices. This will be a measure of central noradrenergic activation (Nater & Rohleder, 2009).
Query!
Assessment method [3]
374189
0
Query!
Timepoint [3]
374189
0
The same time points as the salivary cortisol samples will be used.
Query!
Secondary outcome [4]
374190
0
Skin Conductance Response
This data will be collected using a watch that measures Galvanic Skin Conductance
Query!
Assessment method [4]
374190
0
Query!
Timepoint [4]
374190
0
5 min before the BAT at pre-treatment ( baseline) and during the BAT at Pre-treatment (Week 1)
During VR treatment session 1 and 2 ( Week 1 and 2)
During the BAT at Post-treatment ( Week 3)
During the BAT a Follow-Up (Week 14)
Query!
Secondary outcome [5]
374191
0
Eye gaze responses
This will be obtained using a Virtual Reality headset that measures eye tracking as a measure of attention towards the spider.
Query!
Assessment method [5]
374191
0
Query!
Timepoint [5]
374191
0
During treatment sessions 1 and 2
Query!
Secondary outcome [6]
374192
0
Subjective US expectancy ratings
These ratings will assess the participants expectancy of harm by measuring their amount of anticipatory fear and the perceived likelihood their feared outcome will occur.
Query!
Assessment method [6]
374192
0
Query!
Timepoint [6]
374192
0
Immediately before and after the BAT at Pre-treatment (baseline- Week 1), Post-treatment( Week 3) and Follow-Up (Week 14).
At the start and end of each exposure task during VR treatment sessions ( Week 1 and 2).
Query!
Secondary outcome [7]
374193
0
DAS-21 (Lovibond & Lovibond, 1995)
This questionnaire will be used to measure the emotional states of depression, anxiety and stress
Query!
Assessment method [7]
374193
0
Query!
Timepoint [7]
374193
0
1 time shortly before the BAT at pre-treatment (baseline), post-treatment(Week 3) and follow-Up (Week 12).
Query!
Secondary outcome [8]
376756
0
Skin Conductance Response (SCR)
This data will be collected using the same watch that measures Galvanic Skin Conductance
Query!
Assessment method [8]
376756
0
Query!
Timepoint [8]
376756
0
The same time points used for SCR
Query!
Eligibility
Key inclusion criteria
Participants between the ages of 18 and 60 who diagnostic criteria for a specific phobia of spiders (DSM-V).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Currently engaged in other active psychological or pharmacological treatment
- Comorbid disorder that is more primary or distressing
- Presence of serious or chronic medical illness
- Substance abuse problems
- Psychosis
- Pregnant and lactating
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The intake process which assesses for eligibility into the study will conducted by an external researcher who will not be involved in the treatment process or testing process.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Subject will be randomly allocated to conditions using randomisation table created by computer software.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
At the end of treatment, participants will be asked to explain what they believed the purpose of the water-based task was.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Data will be entered blindly into SPSS software. Group differences in demographic and clinical characteristics will be analysed with one-way ANOVAs. Two-way repeated measures ANOVAs (with treatment group as the between-subject factor and time as the within-subject factor) will be used to determine the effect stress manipulation on cortisol concentrations and treatment outcomes. One-way ANOVAs and post-hoc t-tests will be used to analyse treatment effects at certain time points. A regression analysis will be used to test variables hypothesised to mediate the effects of stress on the primary treatment outcome.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
16/12/2019
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
28/09/2020
Query!
Actual
Query!
Date of last data collection
Anticipated
11/01/2021
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
14681
0
Brain and Mind Centre - University of Sydney - Camperdown
Query!
Recruitment postcode(s) [1]
27713
0
2050 - Camperdown
Query!
Funding & Sponsors
Funding source category [1]
303641
0
University
Query!
Name [1]
303641
0
University of Sydney
Query!
Address [1]
303641
0
Brain and Mind Centre
94 Mallett St, Camperdown NSW 2050
Query!
Country [1]
303641
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Sydney
Query!
Address
Brain and Mind Centre
94 Mallett St, Camperdown NSW 2050
Query!
Country
Australia
Query!
Secondary sponsor category [1]
304490
0
None
Query!
Name [1]
304490
0
Query!
Address [1]
304490
0
Query!
Country [1]
304490
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
304166
0
The University of Sydney Human Research Ethics Committee 2
Query!
Ethics committee address [1]
304166
0
Level 3, F23 Administration Building
The University of Sydney
NSW 2006 Australia
Query!
Ethics committee country [1]
304166
0
Australia
Query!
Date submitted for ethics approval [1]
304166
0
27/05/2019
Query!
Approval date [1]
304166
0
26/08/2019
Query!
Ethics approval number [1]
304166
0
Query!
Summary
Brief summary
Research has shown that exposure-based treatments are the most effective in treating anxiety and fear-based disorders. However, this treatment has been stuck with its improvement in efficacy for years and more than one third of patients do not respond to treatment or experience a relapse of symptoms. Evidence from human and animal studies have shown that acute stress has the potential to add value to these exposure-based treatments by enhancing the learning and memory process. That is, heightened stress
states (induced via pharmacological or behavioural interventions) have been shown to enhance treatment outcomes ( reduce fear symptoms). There is evidence from laboratory studies that stress-related adjuncts to therapy can generalize learning and reduce relapse. However, this has not been investigated in clinical patients and the mechanisms of these effects are unknown. Therefore, this research aims to investigate the use of stress enhancers to optimising exposure therapy for anxiety disorders and it’s potential to reduce
relapse. It will aim to investigate the mechanisms of these effects in order to inform their clinical application. In this study we will determine whether stress may aid psychotherapy of fear and anxiety disorders by modulating attentional processes, stimulating emotional arousal systems (noradrenaline and cortisol) and by acting as an excitatory stimulus to maximise learning (increasing prediction error) . Therefore, this research offers a promising therapeutic tool to improve symptom remission, relapse rates and cost of psychotherapy for anxiety and fear-based disorders.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
96022
0
Prof Mark Dadds
Query!
Address
96022
0
Brain and Mind centre,
94 Mallett St
Camperdown, NSW, 2050
Query!
Country
96022
0
Australia
Query!
Phone
96022
0
+61 2 9114 4321
Query!
Fax
96022
0
Query!
Email
96022
0
[email protected]
Query!
Contact person for public queries
Name
96023
0
Ms Elpiniki Andrew
Query!
Address
96023
0
Brain and Mind centre,
94 Mallett St
Camperdown, NSW, 2050
Query!
Country
96023
0
Australia
Query!
Phone
96023
0
+61 430 531 090
Query!
Fax
96023
0
Query!
Email
96023
0
[email protected]
Query!
Contact person for scientific queries
Name
96024
0
Ms Elpiniki Andrew
Query!
Address
96024
0
Brain and Mind centre,
94 Mallett St
Camperdown, NSW, 2050
Query!
Country
96024
0
Australia
Query!
Phone
96024
0
+61 430 531 090
Query!
Fax
96024
0
Query!
Email
96024
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF